The AstraZeneca share price is rising fast. Here’s what I’d do now

FTSE 100 pharmaceuticals giant AstraZeneca turned in a good set of results. Is it time to buy right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 pharmaceuticals giant AstraZeneca (LSE: AZN) share price was a big gainer yesterday, rising by 5.5% from the day before as it reported a healthy set of results. Its share price is now close to all-time highs, raising the question – Is this a good time to buy AZN?

Expensive but worthy

I find it helpful to look at the price-to-earnings ratio (P/E) when share prices are rising to get a sense of how expensive the stock really is. From the looks of it, AZN sure is highly priced. Its 12-month trailing P/E is almost 43x compared to 19x for another FTSE 100 pharmaceuticals peer GlaxoSmithKline (GSK). Not to undermine GSK’s value, but I think this is a case of investors putting a premium on AZN rather than a one-off spike in its P/E, considering that it’s been maintained for some time now.

It was my top share for May, after it reported a good set of numbers and my sense was that it would rise from there on. From the time the article was published to now, the share price is up 31% and interestingly enough, the P/E is actually marginally lower than the 45x seen then. As an investor, this tells me that there are capital gains to be made even if the ratio is high, instructive as it is. Also, a high ratio doesn’t indicate that the share price will come off soon. In other words, don’t let a high P/E deter you right now because there are enough reasons that still make AZN attractive.  

Safe haven

It’s a big pharmaceuticals company in an economic environment that continues to look uncertain. A number of other defensive shares have also seen a great run-up in share prices in recent years and AZN is no exception. Its international focus also helps, since it’s not entirely vulnerable to the UK’s fortunes. In the latest earnings release, CEO Pascal Soriot noted “impressive results” in international markets like China, the US and Japan.

Performance boost

Besides this, yesterday’s results showed an 18% increase in product sales at constant exchange rate and core operating profit grew by 41% in the third quarter of 2019. The numbers look good on a year-to-date basis too. I also like that AZN has actually upgraded its sales guidance for the second straight quarter, which basically means that it is expected to continue performing going forward.

Coming back to the original question – should I buy AZN shares now, even with the price rise? I reckon that its share price will rise higher over time if things continue to go the way they are right now. Since we at the Motley Fool are concerned with long-term investments, now is as good a time as any other to buy the share. As is the nature of share prices, there will most likely be short-term dips in the near future, and that should be an opportunity to buy more of AZN. But some can be bought right away, I believe.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

The best time to buy stocks? It might be right now

Short-term issues that delay long-term trends create opportunities to buy stocks. And that could be happening right now with a…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Here’s why Next stock rose 5% and topped the FTSE 100 today

Next was the leading FTSE 100 stock today, rising 5%. Our writer takes a look at why and asks if…

Read more »

Renewable energies concept collage
Investing Articles

Up 458% in a year, could the Ceres Power share price go even higher?

Christopher Ruane reviews some highs and lows of the Ceres Power share price over the years and wonders whether the…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Are the glory days over for Rolls-Royce shares?

Rolls-Royce shares have soared in recent years. Lately, though, they have taken a tumble. Could there be worse still to…

Read more »

Group of friends meet up in a pub
Investing Articles

Are ‘66% off’ Diageo shares a once-in-a-decade opportunity?

Diageo shares have taken another hit in the early weeks of 2026. Are we looking at a massive bargain or…

Read more »

Investing Articles

Meet the UK stock under £1.50 smashing Rolls-Royce shares over the past year

While Rolls-Royce shares get all the attention, this under-the-radar trust has quietly made investors a fortune. But is it still…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Down 19%, the red lights are flashing for Barclays shares!

Barclays shares have fallen almost a fifth in value as the Middle East war has intensified. Royston Wild argues that…

Read more »

Aviva logo on glass meeting room door
Investing Articles

After falling another 5%, are Aviva shares too cheap to ignore?

£10,000 invested in Aviva shares five years ago would have grown 50% by now. But what might the future hold,…

Read more »